GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » Net Interest Income

Orexo AB (FRA:C5G) Net Interest Income : €-4.76 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Orexo AB Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Orexo AB's net interest income for the three months ended in Dec. 2024 was €-1.05 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2024 was €-4.76 Mil.

Orexo AB Net Interest Income Historical Data

The historical data trend for Orexo AB's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB Net Interest Income Chart

Orexo AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.30 -2.75 -2.17 -2.75 -4.37

Orexo AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.80 -0.44 -1.91 -1.36 -1.05

Orexo AB Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Net Interest Income Related Terms

Thank you for viewing the detailed overview of Orexo AB's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Orexo AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » Net Interest Income
Comparable Companies
OSTO:CINPHA OSTO:DICOT OSTO:MOB OSTO:KLAR XSAT:ACUC OSTO:NANEXA OSTO:ERMA OSTO:VIVE OSTO:TOL OSTO:NEWBRY ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
ORXOY:USA ORX:Sweden 0H19:UK C5G:Germany
Address
Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105
Website
https://www.orexo.com
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines